Jiangsu Key Laboratory of Biofunctional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China.
Guangdong Medical University, Dongguan 523808, China.
Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:606-614. doi: 10.1016/j.msec.2018.05.073. Epub 2018 May 29.
Development of pH/GSH/enzyme triple stimuli-responsive drug delivery system is promising for tumor therapy due to more acidic, higher glutathione (GSH) level, and overexpressed trypsin under tumor microenvironment. Herein, keratin/doxorubicin (DOX) complex nanoparticles (KDNPs) were for the first time prepared using a drug-induced ionic gelation technique without cross-linker, organic solvent and surfactant. The resultant KDNPs had high drug loading efficacy and performed considerably stable in aqueous solution. Drug delivery curves showed that KDNPs exhibited triple-responsive characters (pH, GSH, and enzyme). Under tumor microenvironments (acid and high GSH level), KDNPs performed surface charge conversion of negative-to-positive and enhanced permeation retention effect (EPR), which both benefited the drug accumulation. Furthermore, the overexpressed trypsin would cleave the peptide bonds within KDNPs and enhance the DOX release. KDNPs were demonstrated to be internalized by A549 cells through endocytosis by cellular uptake assay. Cytotoxicity assay indicated that KDNPs could inhibit the proliferation of tumor cells efficiently. In vivo cytotoxicity and hemolysis tests suggested that KDNPs exhibited excellent biocompatibility as well as good blood compatibility. In vivo antitumor efficacy demonstrated that KDNPs had a strong antitumor effect similar to that of free DOX, but with nearly no side effects. Intriguingly, KDNPs were able to catalyze endogenous NO donor in blood to release NO in tumor tissue, resulting in the prolonged blood circulation time and improved therapeutic activity of drug. In conclusion, keratin-based drug carriers are potential for cancer therapy in clinical medicine.
由于肿瘤微环境中存在更低的 pH 值、更高的谷胱甘肽(GSH)水平和过度表达的胰蛋白酶,因此 pH/GSH/酶三重刺激响应药物输送系统的发展有望用于肿瘤治疗。本文首次使用无交联剂、有机溶剂和表面活性剂的药物诱导离子凝胶技术制备角蛋白/阿霉素(DOX)复合纳米粒(KDNPs)。所得 KDNPs 具有较高的载药效率,在水溶液中表现出相当稳定的性能。药物释放曲线表明 KDNPs 具有三重响应特性(pH、GSH 和酶)。在肿瘤微环境(酸性和高 GSH 水平)下,KDNPs 表现出表面电荷由负到正的转换和增强的渗透保留效应(EPR),这两者都有利于药物积累。此外,过度表达的胰蛋白酶会在 KDNPs 内切割肽键并增强 DOX 的释放。通过细胞摄取实验证实 KDNPs 通过内吞作用被 A549 细胞内化。细胞毒性实验表明 KDNPs 能够有效地抑制肿瘤细胞的增殖。体内细胞毒性和溶血实验表明 KDNPs 具有良好的生物相容性和血液相容性。体内抗肿瘤疗效表明,KDNPs 具有与游离 DOX 相似的强烈抗肿瘤作用,但几乎没有副作用。有趣的是,KDNPs 能够在肿瘤组织中催化血液中的内源性一氧化氮供体释放 NO,从而延长药物的血液循环时间并提高治疗效果。总之,角蛋白基药物载体具有在临床医学中用于癌症治疗的潜力。